|
Poster number |
Title |
Submitting author |
City and Country |
|
231 |
PRMT5 INHIBITION RESTARTS A PRO-APOPTOTIC PROGRAM AND CREATES VULNERABILITY TO COMBINATION TREATMENT WITH BCL-2 INHIBITOR VENETOCLAX IN MANTLE CELL LYMPHOMA |
Fiona Brown |
Columbus, OH, USA |
|
232 |
CC-99282 IS A NOVEL CEREBLON E3 LIGASE MODULATOR (CELMoD) AGENT WITH POTENT AND BROAD ANTITUMOR ACTIVITY IN PRECLINICAL MODELS OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) |
Antonia Lopez-Girona |
Princeton, NJ, USA |
|
233 |
CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in a spectrum of NHL xenograft models |
David Proia |
Watertown, MA, USA |
|
234 |
Glycoprotein PTGDS Acts as a Potential Target in Diffuse Large B-Cell Lymphoma by regulating MYH9-Wnt-β-catenin/STAT3 axis |
Shunfeng Hu |
Jinan, China |
|
235 |
Clinical application of an ex-vivo platform to guide the choice of drug combinations in relapsed/refractory lymphoma; a prospective study |
Anand Jeyasekharan |
Singapore, Singapore |
|
236 |
TG-1701, a Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies |
Chan Yoon Cheah |
Perth, Australia |
|
237 |
First-MIND: A Phase Ib, open-label, randomized study to assess safety of tafasitamab or tafasitamab + lenalidomide in addition to R‑CHOP in patients with newly diagnosed DLBCL |
David Belada |
Hradec Králové, Czech Republic |
|
238 |
Clinical Activity of Loncastuximab Tesirine plus Ibrutinib in Non-Hodgkin Lymphoma: Updated LOTIS 3 Phase 1 Results |
Julien Depaus |
Yvoir, Belgium |
|
239 |
FINAL ANALYSIS OF A NORDIC LYMPHOMA GROUP PHASE IB/IIA TRIAL OF PIXANTRONE, ETOPOSIDE, BENDAMUSTINE AND, IN CD20-POSITIVE TUMORS, RITUXIMAB IN RELAPSED AGGRESSIVE B- OR T-CELL LYMPHOMAS |
Francesco d'Amore |
Aarhus, Denmark |
|
240 |
Mosunetuzumab monotherapy in elderly/unfit pts with first-line diffuse large B-cell lymphoma (DLBCL): safety and efficacy remain promising with durable complete responses |
Adam Olszewski |
Providence, RI, USA |
|
241 |
Antitumoral activity of the novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling and improvement of anti-CD20 therapy in B-cell non-Hodgkin lymphoma |
Gael Roue |
Badalona, Spain |
|
242 |
Promising clinical data from dose escalation in a Phase Ib/II ongoing study of mosunetuzumab with polatuzumab vedotin for relapsed/refractory B-cell non-Hodgkin’s lymphoma |
Catherine Diefenbach |
New York, NY, USA |
|
243 |
Polatuzumab vedotin + rituximab + lenalidomide in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): primary analysis of a Phase 1b/2 trial |
Catherine Diefenbach |
New York, NY, USA |
|
244 |
Safety and Efficacy of CD37-Targeting Naratuximab Emtansine plus Rituximab in Diffuse Large B-cell Lymphoma and other Non-Hodgkin’s B-cell Lymphomas – a Phase 2 Study |
Moshe Levy |
Dallas, TX, USA, |
|
245 |
PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULATORY THERAPY CRITERIA (LYRIC) IN GATA TRIAL FROM THE LYSA GROUP |
Yassine Al Tabaa |
Montpellier, France |